References
1. Frisch R.E., Revelle R. Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science. 1970; 169 (3943): 397–9. DOI: https://doi.org/10.1126/science.169.3943.397 PMID: 5450378
2. Dedov I.I., Melnichenko G.A., Dzeranova L.K., Andreeva E.N., et al. Russian association of endocrinologists national practice guidelines (clinical signs, diagnosis, differential diagnosis, treatment). Hyperprolactinemia. (Project) https://rae-org.ru/system/files/documents/pdf/giperprolaktinemiya_2021g.pdf
3. Colao A., Di Sarno A., Guerra E., De Leo M., et al. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab. 2006; 2 (4): 200–10. DOI: https://doi.org/10.1038/ncpendmet0160
4. Adamyan L.V., Iarmolinskaia M.I., Suslova E.V. Hyperprolactinemia syndrome: from theory to practice. Problemy Reproduktsii [Russian Journal of Human Reproduction]. 2020; 26 (2): 27‑33. DOI: https://doi.org/10.17116/repro20202602127 (in Russian)
5. Dabbous Z., Atkin S.L. Hyperprolactinaemia in male infertility: Clinical case scenarios. Arab J Urol. 2017; 16 (1): 44‑52. DOI: https://doi.org/10.1016/j.aju.2017.10.002
6. Sengupta P., Dutta S., Karkada I.R., Chinni S.V. Endocrinopathies and Male Infertility. Life (Basel). 2021; 12 (1): 10. DOI: https://doi.org/10.3390/life12010010
7. Fachi M.M., de Deus Bueno L., de Oliveira D.C., da Silva L.L., Bonetti A.F. Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network meta-analysis. J Clin Pharm Ther. 2021; 46 (6): 1549–56. DOI: https://doi.org/10.1111/jcpt.13460
8. Melnichenko G.A., Dzeranova L.K., Pigarova E.A., Vorotnikova S.Yu., Tarasova T.S. The data of national medical interview on hyperprolactinemia treatment in real clinical practice. Ozhirenie i metabolizm [Obesity and Metabolism]. 2016; 13 (2): 14–9. DOI: https://doi.org/10.14341/omet2016214-19 (in Russian)
9. Dzeranova L.K., Vorotnikova S.Yu. Cabergoline: 30-year unity of experience and confidence. Rossiyskii Vestnik Akushera-Ginekologa [Russian Bulletin of Obstetrician-Gynecologist]. 2013; 13 (6): 45‑9. (in Russian)
10. Dzeranova L., Skuridina D., Vorotnicova S., Pigarova E. The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline. Ozhirenie i metabolizm [Obesity and Metabolism]. 2016; 13 (3): 60–3. DOI: https://doi.org/10.14341/omet2016360-63 (in Russian)
11. Glezer A., Bronstein M.D. Prolactinomas, cabergoline, and pregnancy. Endocrine. 2014; 47 (1): 64–9. DOI: https://doi.org/10.1007/s12020-014-0334-7
12. Auriemma R.S., Perone Y., Di Sarno A., Grasso L.F., et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab. 2013; 98 (1): 372–9. DOI: https://doi.org/10.1210/jc.2012-3039 PMID: 23162092.
13. O’Sullivan SM, Farrant MT, Ogilvie CM, Gunn AJ, Milsom SR. An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists. Aust N Z J Obstet Gynaecol. 2020; 60 (3): 405–11. DOI: https://doi.org/10.1111/ajo.13070
14. Souteiro P., Belo S., Carvalho D. Dopamine agonists in prolactinomas: when to withdraw? Pituitary. 2020; 23 (1): 38–44. DOI: https://doi.org/10.1007/s11102-019-00989-1
15. Dedov I.I., Melnichenko G.A., Shestakova M.V., Troshina E.A., et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Ozhirenie i metabolizm [Obesity and Metabolism]. 2018; 15 (1): 53–70. DOI: https://doi.org/10.14341/omet2018153-70 (in Russian)
16. Krivosheeva Yu.G., Ilovayskaya I.A. The prevalence rate of hypopituitarism in patients with pituitary macroadenomas with various hormonal activities. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2021; 49 (4): 261–7. DOI: https://doi.org/10.18786/2072-0505-2021-49-047 (in Russian)
17. Krivosheeva Yu.G., Ilovayskaya I.A. Primary signs of pituitary macroadenomas of diff erent hormonal activity and specialists to whom patients referred at the first time. Medicinskij vestnik Ûga Rossii [Medical Herald of the South of Russia]. 2022; 13 (1): 65–71. DOI: https://doi.org/10.21886/2219-8075-2022-13-1-65-71 (in Russian)
18. Dedov I.I., Melnichenko G.A., Dzeranova L.K., Pigarova E.A., et al. Pituitary incidentalomas: the clinical picture, diagnostics, differential diagnostics, and methods of treatment. Problemi Endocrinologii [Problems of Endocrinology]. 2015; 61 (3): 57–68. DOI: https://doi.org/10.14341/probl201561357-68 (in Russian)
19. Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96 (2): 273–88. DOI: https://doi.org/10.1210/jc.2010-1692 PMID: 21296991.